Seattle Genetics signs GSK licensing deal for $400 million
This article was originally published in Scrip
Executive Summary
Seattle Genetics has agreed a $400 million licensing deal with GlaxoSmithKline for its antibody-drug conjugate technology. The end-of-year collaboration pushes Seattle Genetics' deal-making activity for 2009 above $1 billion.